Peer-reviewed veterinary case report
Anemoside B4 as a safe treatment for pneumonia in dogs
By Ji, Jinzhao et al.·Published in Frontiers in veterinary science·2025·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and safety of anemoside B4 in canine pneumonia treatment: a prospective, randomized controlled trial.
- Species:
- dog
Plain-English summary
A group of 72 dogs with mild to moderate pneumonia was treated with a new medication called anemoside B4 (AB4) to see if it could help them recover faster than traditional treatments. The dogs receiving AB4 showed significant improvements in their symptoms, including reduced fever and breathing difficulties, compared to those given a placebo. By Day 14, more dogs in the AB4 group were considered cured, suggesting that this treatment could be a valuable alternative for managing canine pneumonia.
People also search for: dog pneumonia treatment · anemoside B4 for dogs · canine respiratory disease recovery · how to treat dog pneumonia at home
Abstract
BACKGROUND: Canine pneumonia is a serious respiratory disease often associated with Canine Infectious Respiratory Disease (CIRD). Current treatment strategies primarily rely on antibiotics and corticosteroids; however, the emergence of antibiotic resistance and potential side effects from prolonged corticosteroid use limit the effectiveness of these therapies in clinical practice. These challenges highlight the urgent need for alternative treatments. Anemoside B4 (AB4), derived from the traditional Chinese medicine, has shown promise in preclinical studies for modulating inflammatory responses and improving clinical symptoms of pneumonia. Therefore, AB4 may offer a valuable alternative treatment option for canine pneumonia in veterinary medicine. METHODS: A prospective, randomized controlled trial was conducted at the Veterinary Drug Research and Evaluation Center of South China Agricultural University. Seventy-two dogs with mild-to-moderate pneumonia were randomly assigned to one of three groups: AB4, placebo, or Chuanxinlian injection (CXL). The primary outcome was the effect of AB4 on comprehensive clinical scoring of canine pneumonia; secondary outcomes included recovery times for primary symptoms and efficacy assessments. Additionally, AB4's safety in clinical applications was evaluated. RESULTS: The AB4 group demonstrated significantly lower composite clinical scores on Days 7 and 14 compared to the placebo group (= 0.033 and= 0.000, respectively). Significant differences in recovery times for fever and dyspnea were observed between the AB4 and placebo groups (= 0.041 and= 0.024, respectively). Moreover, the cure rate and overall efficacy on Day 14 were significantly higher in the AB4 group than those in the placebo group (= 0.001 and= 0.009, respectively). CONCLUSION: These findings suggest that AB4 may be a promising treatment option for canine pneumonia, potentially serving as an alternative to traditional therapies. Further research is needed to explore its clinical potential in veterinary medicine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40012747/